Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
Go back to Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B| (NASDAQ: IONS) | Delayed: 76.59 +0.70 (0.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $75.89 | 52 Week High | $62.68 | |||
| Open | $75.89 | 52 Week Low | $19.59 | |||
| Day High | $76.96 | P/E | N/A | |||
| Day Low | $75.77 | EPS | $0.00 | |||
| Volume | 315,110 | |||||
